Lv34
360 积分 2025-04-25 加入
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
5小时前
待确认
In vivo CAR engineering for immunotherapy
9天前
已完结
Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities
17天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
24天前
已完结
Novel strategies to manage CAR-T cell toxicity
25天前
已完结
A review of cancer immunotherapy toxicity
25天前
已完结
Linking tumour angiogenesis and tumour immunity
29天前
已完结
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
29天前
已完结
In vivo CAR engineering for immunotherapy
1个月前
已完结
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
1个月前
已完结
皖公网安备34019202002308
